Oncology Institute (NASDAQ:TOI) Given “Buy” Rating at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Oncology Institute (NASDAQ:TOI) in a research report report published on Monday,Benzinga reports. BTIG Research currently has a $7.00 price target on the stock.

TOI has been the subject of several other reports. Needham & Company LLC restated a “buy” rating and issued a $5.00 price objective on shares of Oncology Institute in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $6.50.

Oncology Institute Stock Performance

Shares of TOI opened at $2.73 on Monday. The stock has a 50-day moving average of $3.08 and a two-hundred day moving average of $3.41. The stock has a market cap of $268.58 million, a P/E ratio of -4.27 and a beta of 0.14. Oncology Institute has a one year low of $0.60 and a one year high of $4.88.

Insider Buying and Selling

In other Oncology Institute news, Director Brad Hively sold 13,333 shares of the company’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $3.77, for a total value of $50,265.41. Following the sale, the director owned 683,721 shares in the company, valued at approximately $2,577,628.17. This represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Oncology Institute

Several large investors have recently made changes to their positions in TOI. LPL Financial LLC boosted its holdings in Oncology Institute by 1.5% during the fourth quarter. LPL Financial LLC now owns 270,885 shares of the company’s stock worth $964,000 after buying an additional 3,900 shares in the last quarter. AQR Capital Management LLC increased its holdings in Oncology Institute by 9.1% in the fourth quarter. AQR Capital Management LLC now owns 48,072 shares of the company’s stock valued at $171,000 after buying an additional 4,007 shares in the last quarter. HighTower Advisors LLC increased its holdings in Oncology Institute by 5.5% in the fourth quarter. HighTower Advisors LLC now owns 85,851 shares of the company’s stock valued at $306,000 after buying an additional 4,489 shares in the last quarter. Cetera Investment Advisers raised its position in shares of Oncology Institute by 35.0% in the second quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after acquiring an additional 4,545 shares during the period. Finally, Larson Financial Group LLC raised its position in shares of Oncology Institute by 19.7% in the fourth quarter. Larson Financial Group LLC now owns 31,468 shares of the company’s stock worth $112,000 after acquiring an additional 5,181 shares during the period. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.